Cancer · 2006 · 49 citations · 23 references
MedicineOncologySurgeryMetastasisSurgical OncologySurvival AnalysisCancer Survival AnalysisGastric CancerGastric DiseasesGastrointestinal Cancer SurgeryLocal RecurrenceSurvival OutcomesModerately Differentiated TumorsOverall Survival After RecurrencePredictors Of Disease RecurrenceR0 ResectionRadical GastrectomyRadical ResectionRecurrenceRecurrence Of Gastric Cancer
BACKGROUND: The effect of the location of disease recurrence after curative (R0) gastrectomy on patient survival has not been elucidated. The authors hypothesized that the location of recurrence would have a significant influence on survival. METHODS: Medical records of all patients who received treatment for gastric cancer at The University of Texas M. D. Anderson Cancer Center between 1985 and 1998 were reviewed. Patients who underwent R0 resection for gastric cancer and subsequently developed localized (anastomotic) recurrence (LR), lymph node (regional) recurrence (NR), or distant metastases (DM) were analyzed for overall survival (OS). All study factors were entered into a Cox proportional hazards model to provide multivariate hazard ratios. The model was adjusted for the effects of primary site of recurrence, histologic grade, patient age, and location of the primary tumor. RESULTS: This retrospective analysis included 227 consecutive patients. The median survival of patients who developed NR (11 months) was similar to that of patients who developed LR (10 months), but both groups had significantly longer median survival compared with patients who developed DM (7 months; log-rank P = .03). Patients who had well differentiated or moderately differentiated tumors had a longer OS (11 months) than patients who had poorly differentiated tumors (8 months; log-rank P = .02). In this cohort, location of the primary cancer and age at recurrence had no significant impact on OS. CONCLUSIONS: The data from this study suggested that, among patients who undergo R0 gastrectomy for gastric cancer, LR and NR versus DM should be considered a valid stratification factor for randomized trials based on significant differences in survival. Determining whether this stratification should apply to histologic differentiation will require further investigation in a larger multicenter cohort.
23
Extended Lymph-Node Dissection for Gastric Cancer
Johannes J. Bonenkamp, J. Hermans, Mitsuru Sasako et al. · New England Journal of Medicine · 1999 · 1.6K citations · Full text
H. J. Wanebo, B. J. Kennedy, Joan S. Chmiel et al. · Annals of Surgery · 1993 · 681 citations · Full text
Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer
Jin‐Pok Kim, Joo‐Ho Lee, Soo-Jin Kim et al. · Gastric Cancer · 1998 · 270 citations · Full text